Nuveen’s Aimmune Therapeutics AIMT Stock Holding History

Nuveen’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-178,595	Closed	-$2.25M	–	3405
2020 Q3	$2.25M	Sell	178,595 -11,823	-6%	-$252K	﹤0.01%	2324
2020 Q2	$3.18M	Buy	190,418 +1,841	+1%	+$31.3K	﹤0.01%	2127
2020 Q1	$2.72M	Buy	188,577 +2,824	+2%	+$72.2K	﹤0.01%	2035
2019 Q4	$6.22M	Sell	185,753 -4,847	-3%	-$135K	﹤0.01%	1870
2019 Q3	$3.99M	Sell	190,600 -55	-0%	-$1.12K	﹤0.01%	2076
2019 Q2	$3.97M	Buy	+190,655	New	+$3.92M	﹤0.01%	2106

Nuveen's AIMT Position: Q4 2020 in Review

Nuveen sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 178,595 shares — an estimated $2.25M sold.

Nuveen first reported a position in AIMT in Q2 2019 and held it in 6 quarters. The position peaked at $6.22M in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Nuveen reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Nuveen sold 178,595 Aimmune Therapeutics shares in Q4 2020, an estimated $2.25M.
Nuveen first reported a position in Aimmune Therapeutics in Q2 2019 and held it in 6 quarters.
Nuveen's Aimmune Therapeutics position peaked at $6.22M in Q4 2019.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Nuveen's 13F filing for Q4 2020, filed 16 Feb 2021.